

			Quarter ended		Year ended	
Sl. No.	Particulars	31.03.2018	31.12.2017	31.03.2017	31.03.2018	31.03.2017
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
1	Segment wise revenue and results:					
	Segment revenue :					
	a) Pharmaceutical Services and Active Ingredients	7,853	6,895	6,969	27,930	27,832
	b) Global Generics	27,858	30,270	29,169	114,282	115,736
	c) Proprietary Products	847	2,136	969	4,250	2,783
	d) Others	429	389	460	1,840	1,791
	Total	36,987	39,690	37,567	148,302	148,142
	Less: Inter-segment revenue	1,448	1,349	1,448	5,492	6,181
	Add: Other un-allocable income	-	•	-		-
	Total revenue from operations	35,539	38,341	36,119	142,810	141,961
2	Segment results:					
	Gross profit from each segment					
	a) Pharmaceutical Services and Active Ingredients	1,517	1,302	543	4,477	4,497
	b) Global Generics	16,506	17,912	17,024	67,190	71,079
	c) Proprietary Products	726	2,022	410	3,799	1,951
	d) Others	153	181	208	869	853
	Total	18,902	21,417	18,185	76,335	78,380
	Less: Selling and other un-allocable expenditure / (income), net	15,758	15,947	14,814	62,831	62,843
	Total profit before tax	3,144	5,470	3,371	13,504	15,537